chemotherapy | GenomeWeb

chemotherapy

Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.

The circulating tumor cell-based classifier had an overall accuracy of 89 percent for small-cell lung cancer patients, the researchers reported.

Researchers at the annual meeting of the American Association for Cancer Research discussed their efforts to use genomics to protect patients from radiotherapy toxicity.

The study found that Oncotype DX testing was associated with less frequent chemo use among women at a high clinical risk of recurrence and more frequent chemo in women considered low risk.

The study identified five SNPs significantly associated with five-year progression-free survival and defined risk groups with widely different risks of disease recurrence.

Approximately 85 percent of a 51-member panel at the St. Gallen International Breast Cancer Conference supported the use of Oncotype DX to help decide which patients should receive chemotherapy.

Although the studies presented at the San Antonio Breast Cancer Symposium did not resolve questions about the role of CYP2D6 genotypes or myriad other factors contributing to variability in tamoxifen metabolism, an oncologist at the Mayo Clinic offered some recommendations as to the types of studies that will be necessary to fill knowledge gaps in the field.

Researchers from the Japan Breast Cancer Research Group found that Oncotype DX had "significant prognostic value" in identifying the risk of cancer recurrence in Japanese women with estrogen receptor-positive early-stage breast cancer.

The data, which were presented at this year's American Association for Cancer Research annual meeting, represent initial findings from the company's in-house effort to knock down multiple genes simultaneously and a collaboration related to multi-drug resistance of cancer cells.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.